Keros Therapeutics Launches Phase 2 ALS Trial Design with Healey ALS MyMatch
Keros Therapeutics has entered an agreement with Mass General Hospital’s Healey ALS MyMatch program to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients. The biomarker-driven initiative matches genetic and biofluid markers to experimental therapies and aims to identify optimal patient subgroups for future Phase 2/3 studies.
1. Collaboration Details
Keros has entered into an agreement with Mass General Hospital’s Sean M. Healey & AMG Center for ALS to design a Phase 2 clinical trial evaluating its lead candidate, rinvatercept, in patients diagnosed with amyotrophic lateral sclerosis.
2. Rinvatercept Profile
Rinvatercept is a modified activin receptor ligand trap designed to inhibit myostatin and activin A, promoting muscle regeneration and strength; it is currently being developed for both Duchenne muscular dystrophy and ALS to preserve muscle function and improve quality of life.
3. ALS MyMatch Program
The Healey ALS MyMatch initiative uses comprehensive genetic and biofluid markers to match patient subgroups with experimental therapies, conducting early-phase 1b/2a trials across multiple high-enrolling research centers to refine patient selection criteria for subsequent Phase 2/3 studies.
4. Potential Impact on Keros
Participation in the ALS MyMatch program could accelerate Keros’s clinical development timeline, generate validating biomarker data for rinvatercept and strengthen its ALS pipeline, potentially enhancing partnership prospects and overall company valuation ahead of pivotal trials.